Breeze Acquisition Corp. II is a blank check company, or SPAC, formed solely to acquire a private company and take it public through a merger or similar transaction. The company raised $125M in its IPO, with substantially all proceeds held in trust, invested in short-term U.S. treasuries or government money market funds, until a deal closes or the SPAC liquidates. Breeze II targets companies with global operations and differentiated technology, with a focus on healthcare, biotechnology, advanced manufacturing, robotics, and AI. The company has 12 months from IPO close to complete a deal, with the option to extend with shareholder approval. The sponsor, controlled by CEO J. Douglas Ramsey, paid $25,000 for roughly 4.4M founder shares — the standard SPAC "promote" — and also invested $4.475M in private placement units as at-risk capital. Public shareholders can redeem shares at approximately $10.025 each if they dislike the eventual deal or if no deal closes within the window. If no deal is completed, all public shares are redeemed at trust value and Share Rights expire worthless. There is a structural conflict of interest: the sponsor breaks even at approximately $0.93/share, meaning the sponsor is incentivized to close a deal even if it destroys value for public shareholders.